pyrroles and mk 2206
pyrroles has been researched along with mk 2206 in 13 studies
Research
Studies (13)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cao, Y; Chen, JZ; Chen, SF; Han, S | 1 |
| Cheng, AL; Hsu, C; Lee, BS; Liao, SC; Lin, LI; Liou, JY; Ou, DL | 1 |
| Martinho, O; Reis, RM; Zucca, LE | 1 |
| Crafter, C; D'Cruz, CM; Davies, BR; Dudley, P; Guan, N; Hanson, L; Jacobs, V; Jacques, K; James, N; Jenkins, EL; Kodaira, M; Ladd, B; Lindemann, J; Logie, A; Tamura, K; Zinda, M | 1 |
| Cheon, JH; Choi, AR; Kim, HS; Kim, JH; Woo, YH; Yoon, S | 1 |
| Haniuda, M; Hosokawa, Y; Hyodo, T; Karnan, S; Konishi, H; Ota, A; Tsuzuki, S; Wahiduzzaman, M; Yamaji, M | 1 |
| Brunton, VG; Byron, A; Derksen, PWB; Gómez-Cuadrado, L; Mandoli, A; Martens, JH; Rätze, M; Renes, J; Singh, AA; Strengman, E; Stunnenberg, HG; Tenhagen, M; Teo, K; van Amersfoort, M; van Diest, PJ | 1 |
| Chen, Y; Deng, J; Duan, Z; Evers, BM; Ghaffari, S; Guo, W; He, Y; Lin, PC; Lin, Y; Liu, J; Liu, S; Shi, J; Stewart, RL; Tai, F; Wang, C; Wang, Y; Wu, Y; Zeng, L; Zhang, Q; Zhou, BP; Zhou, MM | 1 |
| Guo, Z; He, J; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
| Bjune, K; Naderi, S; Wierød, L | 1 |
| Bowen, JP; Güner, OF; Matesic, DF; Uko, NE | 1 |
| Decaens, T; Lerat, H; Macek Jílková, Z; Marche, PN; Mroweh, M; Roth, G | 1 |
| Chow, Z; Evers, BM; Johnson, J; Lee, E; Rychahou, P; Weiss, HL | 1 |
Reviews
2 review(s) available for pyrroles and mk 2206
| Article | Year |
|---|---|
Akt Pathway Inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Diamines; Drug Design; Heterocyclic Compounds, 3-Ring; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phospholipids; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Thiadiazoles; Thiophenes | 2020 |
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.
Topics: Aminopyridines; Carcinoma, Hepatocellular; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Liver Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Tumor Microenvironment | 2021 |
Trials
1 trial(s) available for pyrroles and mk 2206
| Article | Year |
|---|---|
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Doxycycline; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice, Nude; Mutation, Missense; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Other Studies
10 other study(ies) available for pyrroles and mk 2206
| Article | Year |
|---|---|
Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
Topics: Allosteric Regulation; Allosteric Site; Catalytic Domain; Heterocyclic Compounds, 3-Ring; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Secondary; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Thermodynamics | 2014 |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Everolimus; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptors, Somatomedin; Signal Transduction; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
AXL as a modulator of sunitinib response in glioblastoma cell lines.
Topics: Angiogenesis Inhibitors; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Gene Knockdown Techniques; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sunitinib | 2015 |
Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Inhibitors; Heterocyclic Compounds, 3-Ring; Humans; Morpholines; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles | 2016 |
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inhibitory Concentration 50; Mesothelioma; Oxadiazoles; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinoxalines; Sulfonamides; Thiadiazoles; Thiophenes | 2017 |
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.
Topics: Animals; Autocrine Communication; Breast Neoplasms; Cadherins; Carcinoma, Lobular; Class I Phosphatidylinositol 3-Kinases; Female; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Mice; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Signal Transduction | 2018 |
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
Topics: Acetylation; Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase 6; Female; Forkhead Box Protein O3; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Nude; Nuclear Proteins; Oxadiazoles; Promoter Regions, Genetic; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Sirtuins; Transcription Factors | 2018 |
Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Topics: Animals; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Mice; Nitriles; Phenylthiohydantoin; Pyrroles; Pyrrolidines; Signal Transduction; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2019 |
Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
Topics: Aminopyridines; Animals; Benzimidazoles; CHO Cells; Cricetinae; Cricetulus; Hep G2 Cells; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Phosphorylcholine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, LDL; Ribonucleosides; RNA Stability; RNA, Messenger; Transcriptional Activation | 2019 |
Role of AMPK and Akt in triple negative breast cancer lung colonization.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Energy Metabolism; Female; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; RNA Interference; RNA, Small Interfering; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |